186 related articles for article (PubMed ID: 16323439)
1. The effect of long-term ethanol feeding on efficacy of doxycycline plus rifampicin in the treatment of experimental brucellosis caused by Brucella melitensis in rats.
Yumuk Z; Dundar V
J Chemother; 2005 Oct; 17(5):509-13. PubMed ID: 16323439
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of several antibiotic combinations against Brucella melitensis Rev 1 experimental infection in BALB/c mice.
Grilló MJ; De Miguel MJ; Muñoz PM; Marín CM; Ariza J; Blasco JM
J Antimicrob Chemother; 2006 Sep; 58(3):622-6. PubMed ID: 16849379
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of Brucella melitensis isolates to various antimicrobials in Turkey.
Denk A; Demirdag K; Kalkan A; Ozden M; Cetinkaya B; Kilic SS
Infect Dis (Lond); 2015 Jun; 47(6):364-9. PubMed ID: 25712728
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial susceptibility of
Shevtsov A; Syzdykov M; Kuznetsov A; Shustov A; Shevtsova E; Berdimuratova K; Mukanov K; Ramankulov Y
Antimicrob Resist Infect Control; 2017; 6():130. PubMed ID: 29299304
[TBL] [Abstract][Full Text] [Related]
5. Biotypes and antimicrobial susceptibilities of Brucella isolates.
Bodur H; Balaban N; Aksaray S; Yetener V; Akinci E; Colpan A; Erbay A
Scand J Infect Dis; 2003; 35(5):337-8. PubMed ID: 12875523
[TBL] [Abstract][Full Text] [Related]
6. Tigecycline: its potential for treatment of brucellosis.
Dizbay M; Kilic S; Hizel K; Arman D
Scand J Infect Dis; 2007; 39(5):432-4. PubMed ID: 17464866
[TBL] [Abstract][Full Text] [Related]
7. Epidemiological survey of rifampicin resistance in clinic isolates of Brucella melitensis obtained from all regions of Turkey.
Sayan M; Kılıc S; Uyanık MH
J Infect Chemother; 2012 Feb; 18(1):41-6. PubMed ID: 21826587
[TBL] [Abstract][Full Text] [Related]
8. Rifampicin resistance phenotyping of Brucella melitensis by rpoB gene analysis in clinical isolates.
Sayan M; Yumuk Z; Dündar D; Bilenoglu O; Erdenlig S; Yaşar E; Willke A
J Chemother; 2008 Aug; 20(4):431-5. PubMed ID: 18676221
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of combinations of doxycycline and rifampicin in the therapy of experimental mouse brucellosis.
Shasha B; Lang R; Rubinstein E
J Antimicrob Chemother; 1994 Mar; 33(3):545-51. PubMed ID: 8040118
[TBL] [Abstract][Full Text] [Related]
10. In vitro antimicrobial susceptibility testing of human Brucella melitensis isolates from Qatar between 2014 - 2015.
Deshmukh A; Hagen F; Sharabasi OA; Abraham M; Wilson G; Doiphode S; Maslamani MA; Meis JF
BMC Microbiol; 2015 Jun; 15():121. PubMed ID: 26073177
[TBL] [Abstract][Full Text] [Related]
11. In vitro antimicrobial susceptibility testing of human Brucella melitensis isolates from Ulanqab of Inner Mongolia, China.
Liu ZG; Di DD; Wang M; Liu RH; Zhao HY; Piao DR; Zhao ZZ; Hao YQ; Du YN; Jiang H; Cui BY; Xia XZ
BMC Infect Dis; 2018 Jan; 18(1):43. PubMed ID: 29338693
[TBL] [Abstract][Full Text] [Related]
12. Therapy of experimental murine brucellosis with streptomycin alone and in combination with ciprofloxacin, doxycycline, and rifampin.
Lang R; Shasha B; Rubinstein E
Antimicrob Agents Chemother; 1993 Nov; 37(11):2333-6. PubMed ID: 8285615
[TBL] [Abstract][Full Text] [Related]
13. Nanotherapeutic provides dose sparing and improved antimicrobial activity against Brucella melitensis infections.
Lueth P; Haughney SL; Binnebose AM; Mullis AS; Peroutka-Bigus N; Narasimhan B; Bellaire BH
J Control Release; 2019 Jan; 294():288-297. PubMed ID: 30572034
[TBL] [Abstract][Full Text] [Related]
14. The effect of long-term ethanol feeding on Brucella melitensis infection of rats.
Yumuk Z; Ozdemirci S; Erden BF; Dundar V
Alcohol Alcohol; 2001; 36(4):314-7. PubMed ID: 11468131
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of rifampicin plus doxycycline versus rifampicin plus quinolone in the treatment of brucellosis.
Saltoglu N; Tasova Y; Inal AS; Seki T; Aksu HS
Saudi Med J; 2002 Aug; 23(8):921-4. PubMed ID: 12235463
[TBL] [Abstract][Full Text] [Related]
16. Cell membrane components of Brucella melitensis play important roles in the resistance of low-level rifampicin.
Yang X; Wu T; Liu W; Tian G; Zhao H; Piao D; Jiang H; Wu Q
PLoS Negl Trop Dis; 2020 Dec; 14(12):e0008888. PubMed ID: 33373362
[TBL] [Abstract][Full Text] [Related]
17. Therapy of experimental murine brucellosis with streptomycin, co-trimoxazole, ciprofloxacin, ofloxacin, pefloxacin, doxycycline, and rifampin.
Shasha B; Lang R; Rubinstein E
Antimicrob Agents Chemother; 1992 May; 36(5):973-6. PubMed ID: 1510422
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial susceptibilities of Brucella isolates from various clinical specimens.
Bayram Y; Korkoca H; Aypak C; Parlak M; Cikman A; Kilic S; Berktas M
Int J Med Sci; 2011 Mar; 8(3):198-202. PubMed ID: 21448305
[TBL] [Abstract][Full Text] [Related]
19. Mutant prevention concentrations of tetracycline, rifampicin and ciprofloxacin for Brucellae melitensis.
Coban AY; Tanyel E; Tasdelen Fisgin N; Darka O; Tulek N; Durupinar B
J Chemother; 2007 Oct; 19(5):596-8. PubMed ID: 18073161
[No Abstract] [Full Text] [Related]
20. The effect of the doxycycline-rifampicin and levamisole combination on lymphocyte subgroups and functions of phagocytic cells in patients with chronic brucellosis.
Dizer U; Hayat L; Beker CM; Görenek L; Ozgüven V; Pahsa A
Chemotherapy; 2005 Mar; 51(1):27-31. PubMed ID: 15722630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
